Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1047 First-in-Human Dose Escalation and Expansion in Malignant Solid Tumors
2024-510722-10-00Phase 2Completed
- Sponsor
- Genmab
- Start
- May 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of GEN1047 in breast cancer, endometrial cancer (EC), ovarian cancer and 2 more, sponsored by Genmab. Primary endpoints: Dose-limiting toxicities (DLTs), Adverse events and safety laboratory parameters (Dose Escalation) and 1 more. Started May 2024; status: completed.
02
Drugs
GEN1047
03
Conditions
breast cancerendometrial cancer (EC)ovarian cancerPulmonary squamous cell carcinomaNon-hematologic malignancy
Beyond the preview
Go deeper on 2024-510722-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510722-10-00.